Multi-omic profiling refines the molecular view

Hurst, Carolyn D.; Knowles, Margaret A.

doi:10.1038/nrclinonc.2017.195

Cited by 22 publications

(17 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TCGA data have provided the comprehensive molecular characterization of MIBCs [ 13 ]; however, the generated results need to be carefully evaluated. TCGA data revealed 58 significantly mutated genes and high frequencies of occurrence of several genetic pathways; however, given the heterogenic nature of MIBCs, the examination of even larger samples is essential to obtain a complete catalogue of mutations or pathways, including those with low frequencies [ 32 ]. Creating a reasonably comprehensive catalogue of candidate cancer genes mutated in ≥2% of patients with MIBCs will require thousands of samples, given the high overall mutation rates of these cancers [ 33 ].…”

Section: Molecular Biomarkers and Pathwaysmentioning

confidence: 99%

“…Creating a reasonably comprehensive catalogue of candidate cancer genes mutated in ≥2% of patients with MIBCs will require thousands of samples, given the high overall mutation rates of these cancers [ 33 ]. Considering the reduced costs of sequencing, a more comprehensive catalogue of MIBCs is likely to be generated in the near future [ 32 ]. Further, almost no studies have replicated the results of the TCGA study [ 13 ]; therefore, it is important that the results be confirmed by other cohorts.…”

Section: Molecular Biomarkers and Pathwaysmentioning

confidence: 99%

“…This subtype frequently has a low CIS score, low levels of tumor-associated extracellular matrix and smooth muscle, a low mutational burden, low levels of hypermethylation and a high frequency of CDKN2A deletions. These tumors express high levels of miR-200 family members, CDH1 and ERBB2 but low levels of miR-99a-5p and miR-100-5p [ 32 ].…”

Section: Classification By Molecular Subtypementioning

confidence: 99%

See 2 more Smart Citations

Bladder Cancer: New Insights into Its Molecular Pathology

Inamura

2018

Cancers

View full text Add to dashboard Cite

Bladder cancer is one of the most prevalent cancers worldwide. Unfortunately, there have been few advances in its clinical management due to a poor understanding of the correlations between its molecular and clinical features. Mounting evidence suggests that bladder cancer comprises a group of molecularly heterogeneous diseases that undergo a variety of clinical courses and possess diverse therapeutic responses. Owing to the close association between its molecular subtypes and clinicopathological features, specific therapeutic strategies have recently been suggested. This review summarizes the current understanding of the molecular pathology of bladder cancer, including its molecular biomarkers/pathways and molecular subtypes that have been newly identified using high-throughput technologies. It also discusses advances in our understanding of personalized treatments for specific molecular subtypes.

show abstract

Section: Molecular Biomarkers and Pathwaysmentioning

confidence: 99%

Section: Molecular Biomarkers and Pathwaysmentioning

confidence: 99%

Section: Classification By Molecular Subtypementioning

confidence: 99%

See 1 more Smart Citation

Bladder Cancer: New Insights into Its Molecular Pathology

Inamura

2018

Cancers

View full text Add to dashboard Cite

show abstract

“…Bladder cancer is the sixth most common cancer in male patients and has a global incidence of over 400,000 new cases per year, with 165,000 bladder-cancer-related deaths each year 1, 2. After bladder cancer progresses to the advanced stage, the only option for treatment is cisplatin-combined chemotherapy 3.…”

Section: Introductionmentioning

confidence: 99%

Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance

Su¹,

Yang²,

Jiang³

et al. 2019

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Hypoxia plays a critical role in cancer biology. It induces genomic instability, which in turn helps cancer cells respond adaptively to meet the needs of carcinogenesis, cancer progression and relapse. Circular RNA has not been reported among the variety of downstream factors in this adaptive response. Although a few studies have demonstrated the important role of circular RNAs in driving human bladder cancer progression, their carcinogenic roles are still under investigated. Here, we identified a hypoxia-elevated circular RNA, circELP3, that contributes to bladder cancer progression and cisplatin resistance. Decreasing the level of circELP3 via siRNA clearly reduced the in vitro proliferation and cisplatin resistance of bladder cancer cells and promoted apoptosis. Interfering with circELP3 suppressed tumor xenograft growth in nude mice in vivo. In addition, lower circELP3-expressing bladder cancer cells displayed poorer self-renewal capacity, as demonstrated by lower levels of sphere formation and stem cell marker expression. Furthermore, in human bladder cancer patients, strong correlations between a high circELP3 level and advanced tumor grade and lymph node metastasis were observed. In summary, we provide the first direct evidence that circular RNA participates in the adaptive response to hypoxia and may play a role in the progression and drug resistance of bladder cancer.

show abstract

“…Bladder cancer is the most common form of urinary tract cancer, leading to >165,000 succumbing to the tumor every year worldwide (5,6). Bladder cancer is a heterogeneous disease with a poor prognosis, indicating the tremendous challenge that the treatment of this disease proposes.…”

Section: Introductionmentioning

confidence: 99%

DNA topoisomerase IIα and RAD21 cohesin complex component are predicted as potential therapeutic targets in bladder cancer

Wang

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Cancer is essentially a genetic disease. Accumulated gene mutations accelerate genome instability, which eventually leads to uncontrollable growth of the tumor. Bladder cancer is the most common form of urinary tract cancer. This form of cancer has a poor prognosis due to its clinical heterogeneity and molecular diversity. Despite recent scientific advances, the knowledge and treatment of bladder cancer still lags behind that of other types of solid tumor. In the present study, available large data portals and other studies were used to obtain clinically relevant information, and the data were systematically processed to decipher the genes associated with bladder cancer. Genes associated with the survival time of patients with bladder cancer were successfully identified. The genes were enriched in common biological processes and pathways, and upregulated in tumor samples from patients. Among the top genes identified as associated with good or poor survival in bladder cancer, DNA topoisomerase IIα (TOP2α) and RAD21 cohesin complex component (RAD21) were also increased in bladder cancer tissues and cell lines. Therefore, TOP2α and RAD21 could be used as potential therapeutic targets in bladder cancer.

show abstract

Multi-omic profiling refines the molecular view

Cited by 22 publications

References 10 publications

Bladder Cancer: New Insights into Its Molecular Pathology

Bladder Cancer: New Insights into Its Molecular Pathology

Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance

DNA topoisomerase IIα and RAD21 cohesin complex component are predicted as potential therapeutic targets in bladder cancer

Contact Info

Product

Resources

About